Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation

Maurizio Taramasso; Francesco Maisano; Azeem Latib; Paolo Denti; Nicola Buzzatti; Micaela Cioni; Giovanni La Canna; Antonio Colombo; Ottavio Alfieri

doi:10.4244/EIJV10I6A128

Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation

Maurizio Taramasso, Francesco Maisano, Azeem Latib, Paolo Denti, Nicola Buzzatti, Micaela Cioni, Giovanni La Canna, Antonio Colombo, Ottavio Alfieri

Research output: Contribution to journal › Article › peer-review

87 Scopus citations

Abstract

Aims: The aim of this study was to report medium-term outcomes of MitraClip implantation in inoperable or high-risk surgical candidates with functional mitral regurgitation (FMR) in our single-centre experience.

Methods and results: From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69±9 years; 82- NYHA Class III-IV). Logistic EuroSCORE was 22±16-. Comorbidities included: chronic renal failure (47-), diabetes (22-), COPD (28-). Mean EF was 28±11-; LVEDD was 68±8 mm. Procedural success was 99- and 30-day mortality was 1.8-. At discharge, 87- patients had MR ≤2+. At 12 months, EF was 34.7±10.4- (p=0.002 compared to preoperative value). Actuarial survival at three years was 74.5±7-. Actuarial freedom from MR ≥3+ at 2.5 years was 70±6-. At one-year follow-up, 86- of patients were in NYHA Class I-II. Preoperative pro-BNP level ≥1,600 pg/ml was identified as an independent risk factor of mortality at follow-up.

Conclusions: MitraClip therapy for FMR is a valuable alternative to surgery in high-risk patients. Higher preoperative pro-BNP level is a risk factor for mortality at follow-up. Although patients treated in current practice are high-risk, the procedure remains safe and effective in selected patients.

Original language	English (US)
Pages (from-to)	746-752
Number of pages	7
Journal	EuroIntervention
Volume	10
Issue number	6
DOIs	https://doi.org/10.4244/EIJV10I6A128
State	Published - Oct 1 2014
Externally published	Yes

Keywords

Biochemical markers
Edge-to-edge repair
Mitral valve disease
Valvular heart disease

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4244/EIJV10I6A128

Cite this

@article{0d31d1b9fac94363965e22025b1c27f4,

title = "Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation",

abstract = "Aims: The aim of this study was to report medium-term outcomes of MitraClip implantation in inoperable or high-risk surgical candidates with functional mitral regurgitation (FMR) in our single-centre experience.Methods and results: From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69±9 years; 82- NYHA Class III-IV). Logistic EuroSCORE was 22±16-. Comorbidities included: chronic renal failure (47-), diabetes (22-), COPD (28-). Mean EF was 28±11-; LVEDD was 68±8 mm. Procedural success was 99- and 30-day mortality was 1.8-. At discharge, 87- patients had MR ≤2+. At 12 months, EF was 34.7±10.4- (p=0.002 compared to preoperative value). Actuarial survival at three years was 74.5±7-. Actuarial freedom from MR ≥3+ at 2.5 years was 70±6-. At one-year follow-up, 86- of patients were in NYHA Class I-II. Preoperative pro-BNP level ≥1,600 pg/ml was identified as an independent risk factor of mortality at follow-up.Conclusions: MitraClip therapy for FMR is a valuable alternative to surgery in high-risk patients. Higher preoperative pro-BNP level is a risk factor for mortality at follow-up. Although patients treated in current practice are high-risk, the procedure remains safe and effective in selected patients.",

keywords = "Biochemical markers, Edge-to-edge repair, Mitral valve disease, Valvular heart disease",

author = "Maurizio Taramasso and Francesco Maisano and Azeem Latib and Paolo Denti and Nicola Buzzatti and Micaela Cioni and {La Canna}, Giovanni and Antonio Colombo and Ottavio Alfieri",

year = "2014",

month = oct,

day = "1",

doi = "10.4244/EIJV10I6A128",

language = "English (US)",

volume = "10",

pages = "746--752",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "EuroPCR",

number = "6",

}

TY - JOUR

T1 - Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation

AU - Taramasso, Maurizio

AU - Maisano, Francesco

AU - Latib, Azeem

AU - Denti, Paolo

AU - Buzzatti, Nicola

AU - Cioni, Micaela

AU - La Canna, Giovanni

AU - Colombo, Antonio

AU - Alfieri, Ottavio

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Aims: The aim of this study was to report medium-term outcomes of MitraClip implantation in inoperable or high-risk surgical candidates with functional mitral regurgitation (FMR) in our single-centre experience.Methods and results: From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69±9 years; 82- NYHA Class III-IV). Logistic EuroSCORE was 22±16-. Comorbidities included: chronic renal failure (47-), diabetes (22-), COPD (28-). Mean EF was 28±11-; LVEDD was 68±8 mm. Procedural success was 99- and 30-day mortality was 1.8-. At discharge, 87- patients had MR ≤2+. At 12 months, EF was 34.7±10.4- (p=0.002 compared to preoperative value). Actuarial survival at three years was 74.5±7-. Actuarial freedom from MR ≥3+ at 2.5 years was 70±6-. At one-year follow-up, 86- of patients were in NYHA Class I-II. Preoperative pro-BNP level ≥1,600 pg/ml was identified as an independent risk factor of mortality at follow-up.Conclusions: MitraClip therapy for FMR is a valuable alternative to surgery in high-risk patients. Higher preoperative pro-BNP level is a risk factor for mortality at follow-up. Although patients treated in current practice are high-risk, the procedure remains safe and effective in selected patients.

AB - Aims: The aim of this study was to report medium-term outcomes of MitraClip implantation in inoperable or high-risk surgical candidates with functional mitral regurgitation (FMR) in our single-centre experience.Methods and results: From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69±9 years; 82- NYHA Class III-IV). Logistic EuroSCORE was 22±16-. Comorbidities included: chronic renal failure (47-), diabetes (22-), COPD (28-). Mean EF was 28±11-; LVEDD was 68±8 mm. Procedural success was 99- and 30-day mortality was 1.8-. At discharge, 87- patients had MR ≤2+. At 12 months, EF was 34.7±10.4- (p=0.002 compared to preoperative value). Actuarial survival at three years was 74.5±7-. Actuarial freedom from MR ≥3+ at 2.5 years was 70±6-. At one-year follow-up, 86- of patients were in NYHA Class I-II. Preoperative pro-BNP level ≥1,600 pg/ml was identified as an independent risk factor of mortality at follow-up.Conclusions: MitraClip therapy for FMR is a valuable alternative to surgery in high-risk patients. Higher preoperative pro-BNP level is a risk factor for mortality at follow-up. Although patients treated in current practice are high-risk, the procedure remains safe and effective in selected patients.

KW - Biochemical markers

KW - Edge-to-edge repair

KW - Mitral valve disease

KW - Valvular heart disease

UR - http://www.scopus.com/inward/record.url?scp=84936759628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936759628&partnerID=8YFLogxK

U2 - 10.4244/EIJV10I6A128

DO - 10.4244/EIJV10I6A128

M3 - Article

C2 - 24469474

AN - SCOPUS:84936759628

SN - 1774-024X

VL - 10

SP - 746

EP - 752

JO - EuroIntervention

JF - EuroIntervention

IS - 6

ER -

Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this